SOLANGE RUTAGENGWA: Open Payments
NPI 1144872763 · MISHAWAKA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 24 payments from 12 companies in 2025. Trend: 2023 $425 · 2024 $656 · 2025 $730
Food & beverage: $715Education: $16
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $171 |
| Insulet Corporation | 1 | $143 |
| Otsuka America Pharmaceutical, Inc. | 4 | $107 |
| Calliditas Therapeutics US Inc. | 3 | $77 |
| Travere Therapeutics, Inc. | 2 | $60 |
| SCPHARMACEUTICALS INC. | 2 | $50 |
| Amgen Inc. | 2 | $33 |
| Fresenius USA Marketing, Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
Products named: Kerendia, OMNIPOD, JYNARQUE, TARPEYO, FUROSCIX, KRYSTEXXA, VOYXACT, VELPHORO.
Industry payments across IN — which companies pay providers there.
